MarketCap
Facebook
X
Telegram
Evolent Health Cost of Revenue | EVH
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Evolent Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.48 B | 2.19 B | 1.5 B | 1.04 B | 658 M | 697 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.19 B | 658 M | 1.26 B |
Quarterly Cost of Revenue Evolent Health
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 412 M | 380 M | 344 M | 381 M | 541 M | 540 M | 536 M | 387 M | 352 M | 310 M | - | 267 M | - | - | - | 163 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 541 M | 163 M | 384 M |
Cost of Revenue of other stocks in the Health information services industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
1 B | - | - | $ 27.9 B |  USA |
 |
Accolade
ACCD
|
222 M | - | 0.29 % | $ 206 M | USA |
 |
Computer Programs and Systems
CPSI
|
163 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
3.72 B | - | - | $ 2.94 B | USA |
 |
iCAD
ICAD
|
2.97 M | - | - | $ 102 M | USA |
 |
Akerna Corp.
KERN
|
92 M | - | - | $ 161 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
292 M | - | -10.39 % | $ 886 M | USA |
 |
1Life Healthcare
ONEM
|
441 M | - | - | $ 3.37 B | USA |
 |
NextGen Healthcare
NXGN
|
342 M | - | - | $ 1.6 B | USA |
 |
Premier
PINC
|
269 M | - | - | $ 2.33 B | USA |
 |
R1 RCM
RCM
|
1.16 B | - | - | $ 3.81 B | USA |
 |
Signify Health
SGFY
|
440 M | - | -0.02 % | $ 7.21 B | USA |
 |
NantHealth
NH
|
28.8 M | - | -46.64 % | $ 10.4 M | USA |
 |
SCWorx Corp.
WORX
|
1.96 M | - | - | $ 7.71 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
233 M | - | - | $ 255 M | USA |
 |
American Well Corporation
AMWL
|
116 M | $ 8.43 | -0.82 % | $ 135 M | USA |
 |
GoodRx Holdings
GDRX
|
57.6 M | $ 2.66 | 1.92 % | $ 948 M | USA |
 |
Health Catalyst
HCAT
|
159 M | $ 1.74 | -1.69 % | $ 122 M | USA |
 |
HealthEquity
HQY
|
400 M | $ 85.21 | -1.3 % | $ 7.34 B | USA |
 |
HealthStream
HSTM
|
107 M | $ 25.64 | -1.38 % | $ 770 M | USA |
 |
Omnicell
OMCL
|
681 M | $ 39.05 | 1.43 % | $ 1.79 B | USA |
 |
OptimizeRx Corporation
OPRX
|
35.8 M | $ 4.98 | -1.97 % | $ 92.4 M | USA |
 |
Progyny
PGNY
|
242 M | $ 26.08 | -0.87 % | $ 2.22 B | USA |
 |
Phreesia
PHR
|
71.4 M | $ 9.38 | 0.32 % | $ 560 M | USA |
 |
Schrödinger
SDGR
|
113 M | $ 15.76 | 1.48 % | $ 1.16 B | USA |
 |
So-Young International
SY
|
796 M | $ 1.43 | -7.77 % | $ 111 M |  China |
 |
Teladoc Health
TDOC
|
772 M | $ 8.07 | 6.32 % | $ 1.42 B | USA |
 |
10x Genomics
TXG
|
199 M | $ 34.76 | 8.17 % | $ 4.34 B | USA |
 |
Veeva Systems
VEEV
|
782 M | $ 153.3 | -1.0 % | $ 25.1 B | USA |
 |
Zhongchao
ZCMD
|
6.25 M | $ 0.65 | 3.45 % | $ 2.22 M | China |